Market Closed -
Nasdaq Stockholm
11:29:50 2024-05-03 am EDT
|
5-day change
|
1st Jan Change
|
114.1
SEK
|
+0.80%
|
|
-0.95%
|
+12.75%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
7,359
|
10,846
|
10,462
|
8,439
|
10,219
|
11,522
|
-
|
Enterprise Value (EV)
1 |
7,145
|
9,378
|
8,977
|
6,951
|
8,665
|
10,267
|
10,560
|
P/E ratio
|
39.3
x
|
53.3
x
|
53.3
x
|
22.6
x
|
28
x
|
28.6
x
|
26.4
x
|
Yield
|
0.88%
|
0.64%
|
0.7%
|
1.74%
|
1.88%
|
6.05%
|
6.05%
|
Capitalization / Revenue
|
9.58
x
|
14.5
x
|
13.3
x
|
7.64
x
|
7.88
x
|
8.1
x
|
7.31
x
|
EV / Revenue
|
9.3
x
|
12.6
x
|
11.4
x
|
6.3
x
|
6.68
x
|
7.22
x
|
6.7
x
|
EV / EBITDA
|
27.7
x
|
37.7
x
|
31.9
x
|
18
x
|
18.5
x
|
19.8
x
|
18.6
x
|
EV / FCF
|
61,844,893
x
|
45,704,120
x
|
41,657,791
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
0%
|
0%
|
0%
|
-
|
-
|
-
|
-
|
Price to Book
|
14.5
x
|
5.49
x
|
5.57
x
|
4.28
x
|
5.03
x
|
6.63
x
|
7.8
x
|
Nbr of stocks (in thousands)
|
86,682
|
100,982
|
100,982
|
100,982
|
100,982
|
100,982
|
-
|
Reference price
2 |
84.90
|
107.4
|
103.6
|
83.57
|
101.2
|
114.1
|
114.1
|
Announcement Date
|
2/6/20
|
2/4/21
|
2/4/22
|
2/3/23
|
2/7/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
768.3
|
747.1
|
785.1
|
1,104
|
1,297
|
1,423
|
1,576
|
EBITDA
1 |
258.1
|
248.7
|
281
|
385.3
|
468.4
|
517.6
|
568.4
|
EBIT
1 |
242.5
|
228.2
|
253.7
|
361.5
|
443.1
|
491.3
|
540.7
|
Operating Margin
|
31.56%
|
30.54%
|
32.31%
|
32.74%
|
34.18%
|
34.52%
|
34.3%
|
Earnings before Tax (EBT)
1 |
242.3
|
227.6
|
252.7
|
447.6
|
468.8
|
516.4
|
560.6
|
Net income
1 |
187.3
|
179.7
|
196.3
|
373.6
|
365.4
|
402.8
|
437.2
|
Net margin
|
24.38%
|
24.05%
|
25%
|
33.84%
|
28.18%
|
28.31%
|
27.74%
|
EPS
2 |
2.162
|
2.014
|
1.944
|
3.700
|
3.620
|
3.990
|
4.330
|
Free Cash Flow
|
115.5
|
205.2
|
215.5
|
-
|
-
|
-
|
-
|
FCF margin
|
15.04%
|
27.46%
|
27.45%
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
44.76%
|
82.51%
|
76.69%
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
61.69%
|
114.18%
|
109.78%
|
-
|
-
|
-
|
-
|
Dividend per Share
2 |
0.7500
|
0.6820
|
0.7260
|
1.450
|
1.900
|
6.900
|
6.900
|
Announcement Date
|
2/6/20
|
2/4/21
|
2/4/22
|
2/3/23
|
2/7/24
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q2
|
2022 Q3
|
---|
Net sales
1 |
173.8
|
206.2
|
288.1
|
257.7
|
EBITDA
1 |
73.43
|
58.22
|
107.4
|
98.85
|
EBIT
1 |
67.18
|
53.1
|
101.3
|
93.74
|
Operating Margin
|
38.64%
|
25.75%
|
35.16%
|
36.37%
|
Earnings before Tax (EBT)
1 |
66.94
|
52.63
|
99
|
98.8
|
Net income
1 |
52.84
|
38.3
|
78.54
|
79.5
|
Net margin
|
30.4%
|
18.57%
|
27.26%
|
30.85%
|
EPS
2 |
0.5240
|
0.3800
|
0.7800
|
0.7900
|
Dividend per Share
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/21/21
|
2/4/22
|
7/22/22
|
10/21/22
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
214
|
1,468
|
1,485
|
1,488
|
1,554
|
1,255
|
962
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
116
|
205
|
215
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
37%
|
16%
|
10.8%
|
19.4%
|
18.3%
|
21.4%
|
27.2%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
5.860
|
19.60
|
18.60
|
19.50
|
20.10
|
17.20
|
14.60
|
Cash Flow per Share
|
1.710
|
2.190
|
2.200
|
-
|
-
|
-
|
-
|
Capex
1 |
32.3
|
16.1
|
6.38
|
17.9
|
48.6
|
35
|
36.8
|
Capex / Sales
|
4.21%
|
2.15%
|
0.81%
|
1.62%
|
3.75%
|
2.46%
|
2.33%
|
Announcement Date
|
2/6/20
|
2/4/21
|
2/4/22
|
2/3/23
|
2/7/24
|
-
|
-
|
Last Close Price
114.1
SEK Average target price
140
SEK Spread / Average Target +22.70% Consensus |
1st Jan change
|
Capi.
|
---|
| +12.75% | 1.07B | | +1.45% | 40.51B | | -15.94% | 31.67B | | +52.66% | 24.62B | | -14.50% | 15.65B | | -14.38% | 12.07B | | -9.12% | 11.97B | | -42.56% | 11.61B | | +4.87% | 8.81B | | -4.33% | 8.5B |
Biopharmaceuticals
|